Innovation in European healthcare – what can Sweden learn? - LIF

The list of medical devices to be reimbursed additionally
to the GHS tariffs is constantly being reviewed in order
to meet the reform’s objectives
• Recent attempts at controlling the growth of medical devices’ expenditures:
• Decreasing reimbursement tariffs
• Negotiations price/volume with companies, price regulations
• But difficult to control, evaluate and rationalise very heterogenous devices
• Difficult to distinguish truly innovative products and simple « marketing improvement »
• Difficult to integrate implantable devices in GHS (Ministry of Health’s objective)
REAL COSTS PAYMENT
(expensive drugs, innovative medical devices)
102